Pre-hypertension Clinical Trial
Official title:
University of Alabama at Birmingham CORT Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure
Verified date | January 2021 |
Source | University of Alabama at Birmingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
We propose a novel intervention for reducing BP that could have a preferential impact in patients with hyperuricemia and gout. There is a great need for new anti-hypertensives, particularly among those with gout. The proposed study is novel in its plans to investigate the physiologic mechanisms through which urate contributes to vascular disease and by which ULT may contribute to BP reduction. Also innovative, we will: 1) determine to what extent the described benefit of lowering serum urate extends beyond the adolescent population previously studied into young adults, 2) test whether a urate-lowering approach will benefit individuals that do not yet meet the current definition of hyperuricemia and do not have gout, and 3) begin to explore potential mechanisms for the higher prevalence of hypertension among African-Americans. If successful, this work could translate to the standard of clinical care and to health care recommendations for the population as a whole.
Status | Completed |
Enrollment | 99 |
Est. completion date | August 2018 |
Est. primary completion date | August 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Pre-hypertension or stage I hypertension, defined as the following after the mean of two clinic measurements: - Systolic blood pressure (SBP) = 120 and <160 or; - Diastolic blood pressure (DBP) = 80 and < 100 - Serum urate = 5.0 mg/dL for men or = 4.0 mg/dL for women - Age 18-40 Exclusion Criteria: - Any current pharmacological treatment for hypertension, including diuretics (calcium channel blockers at stable doses were later allowed) - Estimated glomerular filtration rate < 60 mL/min/1.73m2 - Current use of any urate-lowering therapy or statins - Prior diagnosis of gout or past use of urate-lowering therapy for gout - Prior diagnosis of diabetes - Pregnancy, or recent delivery or last trimester pregnancy loss more recent than 3 months - Active smokers - Immune-suppressed individuals including transplant recipients or current use of azathioprine. - Leucopenia with absolute white cell count < 3000 /mL, anemia with hemoglobin < 12 g/dL, or thrombocytopenia with platelet count < 150,000/mL - Individuals of Han Chinese or Thai descent with HLAB5801 genetic phenotype - Serious medical condition that at investigator's judgment precludes utilization of a fixed dose of allopurinol |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
Lead Sponsor | Collaborator |
---|---|
University of Alabama at Birmingham | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Systolic Blood Pressure (SBP) | Compare systolic blood pressure (SBP) captured by wearing a 24 hour ambulatory blood pressure monitor during each phase of treatment (allopurinol 300 mg/day PO or placebo). Change in systolic blood pressure is calculated by comparing SBP at the end of each treatment phase to pre-treatment values. | 4 weeks (pre-treatment vs. post-treatment SBP) | |
Primary | Change in Flow-mediated Arterial Vasodilation | Compare endothelial function as indexed by flow-mediated arterial vasodilation (FMD) within each phase of treatment (allopurinol 300 mg/day PO or placebo). Percent (%) change in FMD is calculated by comparing FMD (%) at the end of each treatment phase to pre-treatment values. | 4 weeks (pre-treatment vs. post-treatment FMD Values (%)) | |
Primary | Change in Serum Levels of High Sensitivity C-reactive Protein | Serum level of high sensitivity C-reactive protein will be reported as a change during treatment phase (allopurinol 300 mg/day PO or placebo). Change in serum level of C-reactive protein is calculated by comparing serum values at the end of each treatment phase to pre-treatment levels. | 4 weeks (pre-treatment vs. post-treatment serum levels) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03313284 -
Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects?
|
N/A | |
Completed |
NCT01741779 -
Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function
|
N/A | |
Withdrawn |
NCT01074918 -
Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00288158 -
Primary Prevention of Hypertension in Obese Adolescents
|
Phase 2 | |
Completed |
NCT01190319 -
Study: Effects of Strawberries on Blood Pressure
|
N/A | |
Completed |
NCT01008176 -
Restoring Sleep Homeostasis to Lower Blood Pressure
|
N/A | |
Unknown status |
NCT02197910 -
Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects
|
N/A | |
Recruiting |
NCT04543656 -
Personalized Blood Pressure Care Using IoMTs and Artificial Intelligence
|
N/A | |
Completed |
NCT03168789 -
Tension Tamer Randomized Control Trial
|
N/A | |
Completed |
NCT00553969 -
Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00170937 -
A 16 Week Study to Evaluate the Effect on Insulin Sensitivity of Valsartan (320 mg) and Hydrochlorothiazide (25 mg) Combined and Alone, in Patients With Metabolic Syndrome
|
Phase 4 | |
Completed |
NCT01741766 -
The Effects of Stretching Training on Arterial Function and Autonomic Control
|
N/A | |
Completed |
NCT02143817 -
Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition
|
N/A | |
Terminated |
NCT00388388 -
Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects
|
Phase 2 | |
Completed |
NCT02148458 -
Short Term Intermittent Fasting and Mediterranean Diet
|
N/A | |
Terminated |
NCT01349114 -
Effect of the Direct Renin Inhibitor Aliskiren on Endothelial Function and Arterial Stiffness in Diabetic Subjects
|
Phase 4 | |
Completed |
NCT01202175 -
Effects of the Beta-blocker Nebivolol (Bystolic) on Subjects With High Normal Blood Pressure and/or a Family History of Hypertension
|
Phase 4 | |
Completed |
NCT00970931 -
Hypertension Prevention in Pre-Hypertensive Individuals
|
Phase 3 | |
Not yet recruiting |
NCT01364675 -
Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects
|
N/A | |
Completed |
NCT01841840 -
The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke
|
N/A |